DaVita earnings event and why it matters for shareholders

DaVita (DVA) just released second quarter 2026 results, with revenue of US$3.55b and net income of US$265.4m, giving investors fresh numbers on profitability and overall business performance.

DaVita’s latest earnings arrive after a strong run in the stock, with the share price at US$227.99 and a year to date share price return of 99.1%. Momentum has cooled in the very short term, with the 7 day share price return down 4.8%. However, the 90 day share price return of 17.6% and 1 year total shareholder return of 62.3% point to a stronger longer term trend as investors reassess growth and risk around the dialysis business.

If DaVita’s move has you looking beyond a single healthcare stock, this is a good moment to see what else is setting up well in the healthcare space via 41 healthcare AI stocks

Bulls see DaVita’s earnings jump and strong multi year share gains as a sign the stock deserves a premium. Bears point to the sharp run up and richer multiples. Is the current valuation still reasonable?

Most Popular Narrative: 9.3% Overvalued

The most followed DaVita narrative puts fair value at $208.57, which sits below the last close at $227.99 and frames the current debate around the stock.

The analysts have a consensus price target of $208.57 for DaVita based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $270.0, and the most bearish reporting a price target of just $145.0.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value sits below today’s price even as earnings are forecast to rise and margins improve? The answer lies in how long term revenue growth, profitability and the future earnings multiple are combined. The narrative focuses on a specific growth path and a lower P/E several years out. The full set of assumptions is what really indicates how demanding the current price might be.

Result: Fair Value of $208.57 (OVERVALUED)

However, there are still clear risks for DaVita investors. These include reimbursement updates that may lag cost inflation and persistent mortality and missed treatments that pressure volumes.

Another View on DaVita’s Valuation

The analyst narrative flags DaVita as about 9.3% overvalued on a fair value of $208.57. Yet the current P/E of 19.4x sits below the US Healthcare industry at 24.9x and the peer average at 32.1x, and also below a fair ratio of 26.8x. If the market moved closer to that fair ratio, today’s pricing could look much less demanding. This raises the question of which signal you treat as more important.

For a closer look at how this earnings based measure stacks up against sector peers and the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on DaVita split between premium pricing and fair value questions, this is a good time to review the data and decide where you stand. To weigh both sides of the story for yourself, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond DaVita?

If DaVita has sharpened your focus on opportunities, do not stop here. Broader research across sectors can help you build a portfolio that fits your goals.

• Spot potential value opportunities early and review screener containing 18 high quality undiscovered gems that may not yet be widely followed by the market.
• Strengthen the core of your portfolio and check out the solid balance sheet and fundamentals stocks screener (49 results) to focus on companies with more resilient finances.
• Reduce portfolio stress and assess 82 resilient stocks with low risk scores that score better on key risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.